CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program [Yahoo! Finance]
CureVac N.V. - Ordinary Shares (CVAC)
Company Research
Source: Yahoo! Finance
Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that GSK has reported positive Phase 2 headline data from the seasonal influenza mRNA vaccine program. The program was fully licensed to GSK under the terms of a licensing agreement announced on July 3, 2024 According to GSK, the data demonstrated positive immune responses against influenza A and B strains compared to the current standard of ca
Show less
Read more
Impact Snapshot
Event Time:
CVAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVAC alerts
High impacting CureVac N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
CVAC
News
- Is the Options Market Predicting a Spike in CureVac (CVAC) Stock? [Yahoo! Finance]Yahoo! Finance
- Is CureVac N.V. (CVAC) the Best German Stock to Buy Now? [Yahoo! Finance]Yahoo! Finance
- CureVac NV (CVAC) Q3 2024 Earnings Call Highlights: Strong Financial Performance and Strategic ... [Yahoo! Finance]Yahoo! Finance
- CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update Accesswire
CVAC
Sec Filings
- 11/12/24 - Form 6-K
- 11/12/24 - Form 6-K
- 11/4/24 - Form 6-K
- CVAC's page on the SEC website